An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.
Details